Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
CompletedNCT04459234
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication). The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression. In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.
Study details
- Official title
- KETACANCER: Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
- Interventions
- Drug: Ketamine use in CLCC sites (indication and administration protocol)
- Sponsor
- Centre Leon Berard
- Start date
- 2021-02-02
- Primary completion
- 2023-02-06
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 12
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient at least 18 years old at the day of consenting to the study * Patient followed for a solid tumour or a hematological malignancy (treated or under treatment) * Patient presenting cancer chronic pain or post cancer treatment pain * Patient followed by a CLCC's intractable chronic pain consultation or centre * Patient with an indication of 1st Ketamine course: * Analgesic treatment of cancer chronic pain * Analgesic treatment for a post-cancer treatment chronic pain * Help for withdrawal from opioid treatment prescribed for a chronic cancer pain * Patient not previously treated by Ketamine * Patient covered by a medical insurance * Patient and/or family did not decline data collection after complete information (information sheet) Exclusion Criteria: * Patient presenting chronic pains not related to cancer or its treatments * Patient with a proven psychotic history * Patient who is not fluent enough in French
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04459234